Sepsis News and Research

Latest Sepsis News and Research

Shock: Norepinephrine favored over dopamine

Physicians treating patients with shock should consider norepinephrine instead of dopamine as a tool for stabilizing blood pressure, according to an editorial in the March 4, 2010, issue of the New England Journal of Medicine (NEJM).

3 Mar 2010

Spectral Diagnostics receives FDA IDE approval for Toraymyxin

BioMS Medical Corp. today reported that Spectral Diagnostics has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered into a services agreement whereby BioMS will assist Spectral, as required, in its commercialization of Toraymyxin(TM), a therapeutic hemoperfusion device for the treatment of severe sepsis. This approval permits Spectral to initiate its planned pivotal trial for Toraymyxin(TM) in the United States.

3 Mar 2010

SCLL signs agreement to provide research and assay services in support of Agennix's talactoferrin program

Stem Cell Innovations announced today that the Company has signed a Master Services Agreement to provide research and assay services in support of Agennix's talactoferrin program. The assay utilizes SCLL's C3A human liver cell line.

3 Mar 2010

Study: Patients with community-acquired pneumonia who develop AKI more likely to die after discharge

Patients hospitalized with even mild to moderate community-acquired pneumonia who develop acute kidney injury (AKI) are more likely to die after discharge than pneumonia patients whose kidneys remain healthy, according to a University of Pittsburgh School of Medicine study in the February issue of Kidney International.

3 Mar 2010

FDA grants approval to Spectral Diagnostics for pivotal trial of Toraymyxin

Spectral Diagnostics Inc., a company developing products for the treatment of sepsis, today announced that the U.S. Food and Drug Administration has granted Investigational Device Exemption (IDE) approval for Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, allowing the Company to conduct a pivotal trial in the United States.

2 Mar 2010

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today its support for the second annual U.S. Rare Disease Day observance on February 28.

1 Mar 2010

HealthGrades America’s 50 Best Hospitals for 2010 identified

The HealthGrades America’s 50 Best Hospitals for 2010 were identified in a report issued today by the leading independent healthcare ratings organization. The analysis, which examined objective patient outcomes over three years at all 5,000 of the nation’s nonfederal hospitals, found that the 50 Best Hospitals had mortality rates that were, on average, 27% lower than other hospitals.

25 Feb 2010

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Pfizer Inc. announced today that the United States Food and Drug Administration has granted approval for Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s 13-valent pneumococcal conjugate vaccine.

25 Feb 2010

Comparison study of two treatment strategies for severe sepsis reveals similar short-term survival rates

A comparison of two strategies for treating severe sepsis or septic shock finds that using lactate levels measured in blood samples showed a similar short-term survival rate compared to a treatment regimen using central venous oxygen saturation measured using a specialized catheter, according to a study in the February 24 issue of JAMA.

24 Feb 2010

HealthGrades names Good Samaritan Hospital as One of America’s 50 Best Hospitals in 2010

Good Samaritan Hospital in Los Angeles is named as One of America’s 50 Best Hospitals in 2010 by HealthGrades, Inc., the nation’s leading independent healthcare ratings organization.

24 Feb 2010

Study says lower-cost hospitals don't have lower quality care for certain illnesses

A study Monday in the Archives of Internal Medicine found little difference in outcomes between hospitals with longer patient stays and shorter ones, which could make it "possible to lower costs in the U.S. system without hurting patients," Reuters reports.

24 Feb 2010

Nitric oxide may play key role in the pathogenesis of neonatal meningitis

Current research suggests that nitric oxide may play a role in the pathogenesis of neonatal meningitis. The related report by Mittal et al, "Inhibition of inducible nitric oxide controls pathogen load and brain damage by enhancing phagocytosis of Escherichia coli K1 in neonatal meningitis," appears in the March 2010 issue of The American Journal of Pathology.

24 Feb 2010

Multidisciplinary rounds may facilitate implementation of best clinical practices: Study

Multidisciplinary care teams consisting of clinicians, nurses and other health care professionals appear to be associated with a lower risk of death among patients in the intensive care unit, according to a report in the February 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. A second report finds that an increasing number of surgical patients are being managed jointly by a surgeon and another clinician, such as a hospitalist or internal medicine sub-specialist.

23 Feb 2010

Hospital-acquired infections increase mortality rate and healthcare costs

Two common conditions caused by hospital-acquired infections (HAIs) killed 48,000 people and ramped up health care costs by $8.1 billion in 2006 alone, according to a study released today in the Archives of Internal Medicine.

23 Feb 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results from additional upcoming studies, will support its regulatory filing in Europe and the US.

16 Feb 2010

Viral Genetics: Company update

Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer to clinical trials.

12 Feb 2010

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

ExThera Medical announced today that the results of a preliminary study (“Cytokines in blood from septic patients interact with surface immobilized heparin”) of its proprietary medical device, Seraph™ extracorporeal affinity therapy, have been published in the current issue of the Journal of the American Society for Artificial Organs (Jan.-Feb. 2010).

9 Feb 2010

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions.

9 Feb 2010

LExICon study evaluating laser assisted lead removal using Spectranetics laser sheath published

Spectranetics Corporation today announced publication of the four-year, retrospective LExICon (Lead Extraction in Contemporary Settings) study in the February 9th issue of the Journal of American College of Cardiology.

3 Feb 2010

Sepsis News and Research

Latest Sepsis News and Research

Shock: Norepinephrine favored over dopamine

Spectral Diagnostics receives FDA IDE approval for Toraymyxin

SCLL signs agreement to provide research and assay services in support of Agennix's talactoferrin program

Study: Patients with community-acquired pneumonia who develop AKI more likely to die after discharge

FDA grants approval to Spectral Diagnostics for pivotal trial of Toraymyxin

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

HealthGrades America’s 50 Best Hospitals for 2010 identified

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Comparison study of two treatment strategies for severe sepsis reveals similar short-term survival rates

HealthGrades names Good Samaritan Hospital as One of America’s 50 Best Hospitals in 2010

Study says lower-cost hospitals don't have lower quality care for certain illnesses

Nitric oxide may play key role in the pathogenesis of neonatal meningitis

Multidisciplinary rounds may facilitate implementation of best clinical practices: Study

Hospital-acquired infections increase mortality rate and healthcare costs

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

Viral Genetics: Company update

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

LExICon study evaluating laser assisted lead removal using Spectranetics laser sheath published

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Sepsis News and Research

Latest Sepsis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in